Product Program year 2023 Source: CMS Open Payments

Otrexup

Drug Antirheumatic

NDC 54436-010-04

Open in the dashboard

General payments

$80,131

48 payments

Research payments

$0

0 payments

Through program year 2023, $80,131 in general payments and $0 in research payments were reported against Otrexup (Antirheumatic).

No combined total These are different kinds of money, reported under different rules. A meal and a clinical trial grant do not add up to anything meaningful, so this site does not add them.

By program year

2 rows
Year Kind Amount Payments
2023 General $6,510 4
2022 General $73,621 44

Breakdown

Who paid General payments · program years 2022–2023
  1. ASSERTIO THERAPEUTICS, Inc. $73,621 44 payments
  2. Otter Pharmaceuticals, LLC $6,510 4 payments
Top recipients General payments · program year 2023
  1. Sarah Paul Pediatric Rheumatology · Morristown, NJ $4,200 65% · 1 payment
  2. Krishna Mallik Orthopaedic Surgery · Scottsdale, AZ $2,310 35% · 3 payments

Each share is of general payments naming this product in 2023.

Specialties paid General payments · program year 2023
  1. Pediatric Rheumatology Pediatrics $4,200 65% · 1 practitioner
  2. Orthopaedic Surgery $2,310 35% · 1 practitioner

Each share is of general payments naming this product to practitioners with a specialty in 2023. Each practitioner is counted under their primary specialty.

Where the money went General payments · program year 2023
  1. New Jersey $4,200 65% · 1 recipient
  2. Arizona $2,310 35% · 1 recipient

Each share is of general payments naming this product in 2023 where a state was reported.

Prescribed to Medicare patients

Part D · data year 2024

Part D claims

3,987

Prescriptions dispensed, refills included

Drug cost

$3,271,896

Paid at the pharmacy, in all

Prescribers

232

With 11 or more claims of it

Medicare Part D drugs matched to OTREXUP, 2024
Part D drug Name match Relative to the largest Prescribers Claims Drug cost
Otrexup Methotrexate/Pf Same name 232 3,987 $3,271,896

Matched to this product by name; CMS does not link its files to Open Payments, so a similar name can be a different strength, form or brand. Prescriber counts include only prescribers with 11 or more claims of the drug, because CMS publishes nothing below that. Part D covers drugs dispensed to Medicare beneficiaries at a pharmacy; it does not include drugs given in a clinic or hospital, or patients with other insurance.

Largest prescribers

First 5 of 100 by claims · 2024

Two separate records. Claims come from Medicare and related payments from Open Payments. They are shown in one row because they name the same product; they do not show that a payment affected a prescription.

The prescribers with the most Part D claims of this drug in 2024
Prescriber Specialty State Claims Drug cost Related payments
Soha Dolatabadi Rheumatology CA 172 $133,163 None on record
Yevgenia Margulis Rheumatology NY 73 $61,099 None on record
Monica Crawford Rheumatology AL 69 $50,776 None on record
Jonathan Dunham Rheumatology PA 49 $40,870 No profile
Irina Buhaescu Rheumatology MA 49 $36,971 No profile

"No profile" means the prescriber has no Open Payments record here; "None on record" means no payment naming this product in the payment year. Related payments are general payments, and one that names several products is split evenly, so an amount is payments related to the product, not money paid for it. The list is the prescribers with the most claims, up to 100 per drug.

See more in the dashboard: 25 with a free account, all 100 with Patron
48 general

Every payment, record by record

Date, amount, who was paid and what for — filter by year and kind, or download as CSV, free, in files of 5,000 rows.

What you are looking at

Manufacturers name the drug, biological or device a payment relates to. CMS does not give products their own identifiers, so a product here is assembled from how it was reported — a brand may appear under more than one spelling, and this page covers one of them rather than the brand as a whole.

Provenance

Source: CMS Open Payments · through program year 2023

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record